Nulojix
Chemical Name | belatacept |
Dosage Form | Injection (intravenous; 250 mg) |
Drug Class | Selective T-cell costimulation blockers |
System | Multiple |
Company | Bristol Myers Squibb |
Approval Year | 2011 |
Indication
- Indicated in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids for prophylaxis of organ rejection in adult patients receiving a kidney transplant.